|
|
|
With the expected changes in demographics over the next 10-15 years, there is a growing need to increase and accelerate the development of safe and effective therapies for eye disorders. Charles River has the necessary understanding of eye-related diseases and conditions as well as the technical ability and experience to guide your new drugs and treatments through the development process as efficiently as possible.
Through our Research Models and Preclinical Services groups, we offer you an integrated approach to ophthalmology research. Compounds or implantable devices intended for ocular treatment can be assessed for efficacy, safety and toxicity. In addition, ocular effects of compounds targeted to non-ocular conditions can also be characterized.
- Research models
- Specialty models (list not all-inclusive)
- Choroidal neovascularization (CNV) models
- Streptozotocin (STZ) – induced diabetic retinopathy
- Retinal degeneration
- Intraocular lens (IOL)
- Corneal pouch
- Corneal epithelial wound healing
- Gland removal for dry eye model
- Multiple species and dosing routes
- Safety assessment
- Board-certified veterinary ophthalmologists
- Pathology
- Phototoxicology
- Tissue/organ imaging and photography
- Drug metabolism and pharmacokinetics
|
|
|
|
|
Ophthalmology, ocular, retinal, corneal, eye, non-ocular, Choroidal neovascularization, CNV, Streptozotocin, STZ, retinopathy, Retinal degeneration, Intraocular lens, Corneal pouch, dry eye
Ophthalmology Research and Drug Development | Charles River
Charles River has the necessary understanding of eye-related diseases and conditions as well as the technical ability and experience to guide your new ocular drugs and treatments through the development process as efficiently as possible.